ARQT - Latest News
Arcutis Biotherapeutics, Inc. (ARQT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.32B. Trailing twelve-month P/E ratio is 120.87. Beta to the broader market is 1.58.
The article list below shows the most recent ARQT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ARQT Headlines
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
globenewswire.com - Oct 9, 2026
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
globenewswire.com - Oct 6, 2026
Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0. 15% for mild to moderate atopic dermatitis (eczema)
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages
defenseworld.net - Oct 3, 2026
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages tha
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Oct 2, 2026
WESTLAKE VILLAGE, Calif. , Oct.
Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
defenseworld.net - Sep 20, 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction that
How News Affects ARQT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ARQT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ARQT news questions
- What is the latest ARQT news headline?
- The most recent ARQT headline (Oct 9, 2026) is "Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ARQT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ARQT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ARQT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.